JP5808249B2 - プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製 - Google Patents

プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製 Download PDF

Info

Publication number
JP5808249B2
JP5808249B2 JP2011532332A JP2011532332A JP5808249B2 JP 5808249 B2 JP5808249 B2 JP 5808249B2 JP 2011532332 A JP2011532332 A JP 2011532332A JP 2011532332 A JP2011532332 A JP 2011532332A JP 5808249 B2 JP5808249 B2 JP 5808249B2
Authority
JP
Japan
Prior art keywords
antibody
sample
antibodies
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011532332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506383A (ja
Inventor
ヒツクマン，ロバート・ケイ
ホワン，チン
ウイード，シエリル・エル
エニス，スコツト・テイー
ペリリ−パーマー，バーバラ
ワン，ミン
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41835469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5808249(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2012506383A publication Critical patent/JP2012506383A/ja
Application granted granted Critical
Publication of JP5808249B2 publication Critical patent/JP5808249B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011532332A 2008-10-20 2009-10-20 プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製 Active JP5808249B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19675308P 2008-10-20 2008-10-20
US61/196,753 2008-10-20
PCT/US2009/061329 WO2010141039A1 (en) 2008-10-20 2009-10-20 Isolation and purification of antibodies using protein a affinity chromatography

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014195268A Division JP2015042645A (ja) 2008-10-20 2014-09-25 プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製

Publications (2)

Publication Number Publication Date
JP2012506383A JP2012506383A (ja) 2012-03-15
JP5808249B2 true JP5808249B2 (ja) 2015-11-10

Family

ID=41835469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011532332A Active JP5808249B2 (ja) 2008-10-20 2009-10-20 プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
JP2014195268A Ceased JP2015042645A (ja) 2008-10-20 2014-09-25 プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014195268A Ceased JP2015042645A (ja) 2008-10-20 2014-09-25 プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製

Country Status (18)

Country Link
US (5) US8895709B2 (OSRAM)
EP (2) EP2921501A1 (OSRAM)
JP (2) JP5808249B2 (OSRAM)
KR (1) KR20110091678A (OSRAM)
CN (2) CN105111309A (OSRAM)
AU (4) AU2009347206C1 (OSRAM)
BR (1) BRPI0920027A2 (OSRAM)
CA (3) CA2932207A1 (OSRAM)
ES (1) ES2535734T3 (OSRAM)
HK (1) HK1209428A1 (OSRAM)
IL (3) IL211918A (OSRAM)
MX (3) MX2011004200A (OSRAM)
NZ (1) NZ592095A (OSRAM)
RU (1) RU2520838C2 (OSRAM)
SG (1) SG10201702922VA (OSRAM)
TW (2) TWI610936B (OSRAM)
WO (1) WO2010141039A1 (OSRAM)
ZA (1) ZA201102523B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015042645A (ja) * 2008-10-20 2015-03-05 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
US8262912B1 (en) * 2009-06-05 2012-09-11 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
US9056265B2 (en) 2009-06-05 2015-06-16 Tenfold Technologies, LLC Isolated bioactive compounds and method of use
PL2473617T3 (pl) * 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
CN105107228B (zh) * 2010-12-06 2017-03-29 颇尔公司 生物制品的连续加工方法
US20120238730A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012151199A1 (en) * 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2012160536A1 (en) * 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
SG195306A1 (en) * 2011-06-08 2013-12-30 Agency Science Tech & Res Purification of biological products by constrained cohydration chromatography
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
US20130129718A1 (en) * 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
EP2850099B1 (en) 2012-05-14 2017-01-18 Novo Nordisk A/S Stabilised protein solutions
US20140154270A1 (en) * 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
US20130336957A1 (en) * 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150133643A1 (en) * 2012-06-06 2015-05-14 Emd Millipore Corporation Low Organic Extractable Depth Filter Media Processed with Solvent Extraction Method
SG11201406407TA (en) * 2012-06-29 2014-11-27 Emd Millipore Corp Methods for inactivating viruses during a protein purification process
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2894159A4 (en) 2012-09-03 2016-01-20 Kaneka Corp MIXING MODE ANTIBODY SAFFINITY MIXTURE AND PURIFICATION PROCESS WITH AND TARGET MOLECULE
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
WO2014102814A1 (en) * 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
IL274646B (en) 2013-03-08 2022-09-01 Genzyme Corp Integrated continuous production of medicinal substances from medical protein
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2970375A1 (en) * 2013-03-14 2016-01-20 AbbVie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
CA2910065C (en) 2013-05-15 2023-09-19 Medimmune Limited Purification of recombinantly produced polypeptides
KR101569783B1 (ko) * 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3019262A1 (en) 2013-07-12 2016-05-18 Merck Patent GmbH Removal of fragments from a sample containing a target protein using activated carbon
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
IL244149B2 (en) 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
US10519195B2 (en) 2013-09-17 2019-12-31 Kaneka Corporation Antibody purification method, antibody obtained therefrom, novel antibody purification method using cation exchanger, and antibody obtained therefrom
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TWI715524B (zh) * 2013-12-27 2021-01-11 日商中外製藥股份有限公司 等電點低之抗體的精製方法
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
HUE048782T2 (hu) 2014-03-10 2020-08-28 Richter Gedeon Nyrt Immunoglobulin tisztítása elõtisztítási lépések alkalmazásával
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
JP6630036B2 (ja) * 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
CN105566442A (zh) * 2014-10-11 2016-05-11 江苏泰康生物医药有限公司 一种降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化工艺
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EA035635B1 (ru) * 2015-03-13 2020-07-17 Бристол-Маерс Сквибб Компани Использование щелочных промывочных растворов во время хроматографии для удаления примесей
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
RU2737539C2 (ru) * 2016-04-01 2020-12-01 Юсб Биофарма Спрл Способ очистки белка
IL290358B2 (en) 2016-04-14 2024-03-01 Lonza Ag Preparations and methods for detecting host cell proteins
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
EP4071469B1 (en) 2016-10-25 2025-04-09 Regeneron Pharmaceuticals, Inc. Methods for chromatography data analysis
IL317014A (en) * 2016-12-09 2025-01-01 Gliknik Inc Production optimization of GL-2045, a multimerization sterol.
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
RS63533B1 (sr) 2016-12-23 2022-09-30 Serum Institute Of India Pvt Ltd Postupci za povećanje produktivnosti antitela u kulturi sisarskih ćelija i smanjenje agregacije tokom nishodne obrade, postupci formulacije i rezultujuće stabilne formulacije antitela
CN111344410B (zh) 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
CN110997133A (zh) * 2017-08-23 2020-04-10 Jsr株式会社 色谱用载体、配体固定载体、色谱柱、靶物质的纯化方法和色谱用载体的制造方法
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
EP3728288B1 (en) * 2017-12-21 2022-01-19 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CN108239146A (zh) * 2018-03-26 2018-07-03 江苏中新医药有限公司 一种高纯度rhNGF的制备方法
WO2019204747A1 (en) 2018-04-20 2019-10-24 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
BR112021003420A2 (pt) * 2018-08-31 2021-05-18 Genzyme Corporation resina cromatográfica estéril e uso da mesma em processos de manufatura
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
KR20210096633A (ko) * 2018-11-29 2021-08-05 리폼 바이오로직스, 엘엘씨 단백질 처리를 위한 부형제 화합물
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
WO2020247574A1 (en) * 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
MX2023003836A (es) * 2020-10-02 2023-04-14 Lilly Co Eli Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113501857A (zh) * 2021-08-17 2021-10-15 沈阳百发科技有限公司 一种高活性重组蛋白的制备方法
CN114292328B (zh) * 2021-12-30 2025-07-25 武汉原谷生物科技有限责任公司 一种来源于美洲羊驼中天然抗体的纯化方法及其应用
US20250076264A1 (en) * 2022-01-24 2025-03-06 University Of Florida Research Foundation, Incorporated Point of care testing system for antithrombin iii
CN115073590A (zh) * 2022-07-08 2022-09-20 杭州艾策生物技术有限公司 一种减少单克隆抗体氧化杂质的深层过滤方法
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
JPS59156299A (ja) 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
PT802257E (pt) 1996-04-19 2003-01-31 Nestle Sa Linhagem imortalizada de celulas epiteliais do colon humano
WO1998017786A1 (en) 1996-10-23 1998-04-30 Oravax, Inc. Heat inactivation of viruses in antibody preparations
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
DK0950067T3 (da) 1996-11-27 2007-12-27 Genentech Inc Affinitetsoprensning af polypeptid på protein A-matrix
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
WO1999032605A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE474052T1 (de) 1999-09-27 2010-07-15 Genentech Inc Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
ATE329018T1 (de) 2000-02-08 2006-06-15 Genentech Inc Verbesserte galactosylierung von rekombinanten proteinen
HUP0300423A3 (en) 2000-02-10 2008-07-28 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
EP1175931A1 (en) 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
ES2321539T3 (es) 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL368119A1 (en) 2001-10-02 2005-03-21 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
CA2466881A1 (en) 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
JP4363986B2 (ja) 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
US20030201229A1 (en) 2002-02-04 2003-10-30 Martin Siwak Process for prefiltration of a protein solution
WO2003066662A2 (en) 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US20030190710A1 (en) 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
RU2304587C2 (ru) * 2002-06-10 2007-08-20 Гуд Байотек Копэрейшн СПОСОБ СЕЛЕКТИВНОГО ВЫДЕЛЕНИЯ АНТИТЕЛ IgY ИЗ ЯИЧНОГО ЖЕЛТКА ПТИЦ ОТРЯДА ГУСЕОБРАЗНЫХ (ВАРИАНТЫ)
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
JP2006508062A (ja) * 2002-09-17 2006-03-09 ジーティーシー バイオセラピューティックス インコーポレイテッド 重鎖間ジスルフィド結合を欠く免疫グロブリン分子の単離
US7208585B2 (en) 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
TWI328614B (en) 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
CA2511520A1 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
GB2404665B (en) 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
EP1673452B1 (en) 2003-10-10 2015-12-23 Novo Nordisk Health Care AG Method for large-scale production of a polypeptide in eukaryote cells
BR122020007658B1 (pt) 2003-10-27 2021-07-27 Wyeth Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400886D0 (sv) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
EP1807101B1 (en) 2004-09-30 2016-04-13 Bayer Healthcare LLC Devices and methods for integrated continuous manufacturing of biological molecules
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP2006143601A (ja) 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
CN101120085B (zh) 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
RU2457214C2 (ru) 2005-03-11 2012-07-27 Вайет Способ хроматографии в режиме слабого распределения
NZ562949A (en) 2005-04-11 2009-05-31 Medarex Inc Protein purification using HCIC and ion exchange chromatography
WO2006113743A2 (en) 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US7247457B2 (en) 2005-04-26 2007-07-24 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
EP1896504B1 (en) 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
SI1917276T1 (en) 2005-08-26 2018-05-31 Ares Trading S.A. PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
RU2008150314A (ru) 2006-05-19 2010-06-27 Гликофи, Инк. (Us) Композиции эритропоэтина
JP2010510963A (ja) 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
WO2008007280A2 (en) 2006-06-28 2008-01-17 Koninklijke Philips Electronics N.V. Assay system and method
ES2440487T3 (es) 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
PL2061803T5 (pl) 2006-08-28 2023-03-27 Ares Trading S.A. Proces oczyszczania białek zawierających fc
AU2007292253A1 (en) 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
EP2500413A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008036600A2 (en) 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
US20110105734A1 (en) 2006-12-06 2011-05-05 Jcr Pharmaceuticals Co., Ltd. Method for production of human erythropoietin
WO2008079302A2 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
MX2009010492A (es) * 2007-03-30 2009-10-19 Abbott Lab Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
EP2134853B1 (en) 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP1988101A1 (en) 2007-05-04 2008-11-05 Novo Nordisk A/S Improvement of factor VIII polypeptide titers in cell cultures
WO2008135498A2 (en) 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
ES2392701T3 (es) 2007-05-11 2012-12-13 Amgen Inc. Medios de alimentación mejorados
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
PL2188302T3 (pl) 2007-07-09 2018-04-30 Genentech, Inc. Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
TWM332870U (en) * 2007-11-22 2008-05-21 Delta Electronics Inc Side-edge type backlight module
RU2473360C2 (ru) 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
KR101798813B1 (ko) 2007-12-27 2017-11-16 박스알타 인코퍼레이티드 세포 배양 방법
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
US20110003338A1 (en) 2008-03-11 2011-01-06 Robert Bayer Antibodies with enhanced adcc function
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2331700A2 (en) 2008-08-08 2011-06-15 Biogen Idec MA Inc. Nutrient monitoring and feedback control for increased bioproduct production
US10927144B2 (en) 2008-08-14 2021-02-23 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
US8025879B2 (en) 2008-09-26 2011-09-27 Eureka Therapeutics, Inc. Modified glycoproteins and uses thereof
TW201024319A (en) 2008-10-20 2010-07-01 Abbott Lab Antibodies that bind to IL-12 and methods of purifying the same
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
CN102257007A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 与il-18结合的抗体及其纯化方法
CA2739568C (en) 2008-10-31 2015-12-01 Shujun Sun Purification of acidic proteins using ceramic hydroxyapatite chromatography
WO2010066634A1 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
AU2009331897A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Immunoglobulin purification
EP2373676B1 (en) 2009-01-08 2017-04-19 GE Healthcare BioProcess R&D AB Separation method using single polymer phase systems
JP5728392B2 (ja) 2009-03-05 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 免疫グロブリンの精製
JP5755136B2 (ja) 2009-03-27 2015-07-29 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法
TW201041899A (en) 2009-04-13 2010-12-01 Bristol Myers Squibb Co Protein purification by citrate precipitation
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
JP2012527879A (ja) 2009-05-28 2012-11-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 合理的な細胞培養プロセスのための方法
AU2010256455A1 (en) 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120329151A1 (en) 2009-07-06 2012-12-27 F. Hoffmann-La Roche Ag Method of culturing eukaryotic cells
US20120177640A1 (en) 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
ES2662529T3 (es) 2009-08-06 2018-04-06 F. Hoffmann-La Roche Ag Procedimiento para mejorar la eliminación de virus en la purificación de proteínas
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
WO2011024025A1 (en) 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
PL2473617T3 (pl) 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011050071A2 (en) * 2009-10-20 2011-04-28 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
EP2507627A2 (en) 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
PL3272764T3 (pl) 2009-12-18 2024-06-10 Novartis Ag Sposób chromatografii powinowactwa
WO2011087301A2 (ko) 2010-01-15 2011-07-21 성균관대학교산학협력단 기체 및 수분 차단용 그래핀 보호막, 이의 형성 방법 및 그의 용도
EP2556137B1 (en) 2010-04-06 2015-06-03 Heliae Development LLC Methods of and systems for producing biofuels
EP2556163B1 (en) 2010-04-07 2016-08-10 Momenta Pharmaceuticals, Inc. Method for quantifying high mannose containing glycoforms
CN102858954A (zh) 2010-04-26 2013-01-02 诺瓦提斯公司 改进的细胞培养方法
PL2563904T3 (pl) 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej
KR101869987B1 (ko) 2010-05-28 2018-07-20 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2618904A1 (en) * 2010-09-20 2013-07-31 AbbVie Inc. Purification of antibodies using simulated moving bed chromatography
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
EP2649087A1 (en) 2010-12-08 2013-10-16 Amgen Inc. Ion exchange chromatography in the presence of an amino acid
US20140162317A1 (en) 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
BR112013022832A2 (pt) 2011-03-06 2016-11-22 Merck Serono Sa linhagens de células de baixo teor de fucose e usos das mesmas
US10906934B2 (en) 2011-03-25 2021-02-02 Genentech, Inc. Protein purification methods
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
CN105189735B (zh) 2011-04-29 2019-04-12 拜康研究有限公司 在培养期间减少乳酸累积的方法和生产多肽的方法
US20120283419A1 (en) 2011-05-03 2012-11-08 Avantor Performance Materials, Inc. Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
EP2707383B1 (en) 2011-05-13 2018-04-18 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
KR20230114317A (ko) 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
WO2013006461A1 (en) 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
EP2768845B1 (en) 2011-10-19 2017-01-18 Roche Glycart AG Separation method for fucosylated antibodies
US9150645B2 (en) * 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015042645A (ja) * 2008-10-20 2015-03-05 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製

Also Published As

Publication number Publication date
AU2016222301A1 (en) 2016-09-15
ZA201102523B (en) 2011-12-28
AU2015207915C1 (en) 2016-12-08
AU2015207915A1 (en) 2015-08-20
AU2018203810A1 (en) 2018-06-21
AU2015207915B2 (en) 2016-06-02
CN105111309A (zh) 2015-12-02
IL244157A0 (en) 2016-04-21
IL232601A0 (en) 2014-06-30
SG10201702922VA (en) 2017-06-29
US9018361B2 (en) 2015-04-28
CA2911256A1 (en) 2010-12-09
AU2009347206A1 (en) 2010-12-09
US20140255423A1 (en) 2014-09-11
AU2009347206A8 (en) 2011-05-26
AU2009347206C1 (en) 2016-12-08
ES2535734T3 (es) 2015-05-14
HK1209428A1 (en) 2016-04-01
TWI610936B (zh) 2018-01-11
EP2350127B1 (en) 2015-01-28
EP2921501A1 (en) 2015-09-23
IL211918A (en) 2016-03-31
JP2012506383A (ja) 2012-03-15
JP2015042645A (ja) 2015-03-05
CN102257006A (zh) 2011-11-23
RU2520838C2 (ru) 2014-06-27
CA2738498A1 (en) 2010-12-09
US20170158760A1 (en) 2017-06-08
EP2350127A1 (en) 2011-08-03
TW201024318A (en) 2010-07-01
RU2011120191A (ru) 2012-11-27
MX2018014395A (es) 2020-07-29
NZ592095A (en) 2013-01-25
TW201634476A (zh) 2016-10-01
MX343087B (es) 2016-10-14
CA2932207A1 (en) 2010-12-09
KR20110091678A (ko) 2011-08-12
IL211918A0 (en) 2011-06-30
US20100135987A1 (en) 2010-06-03
MX2011004200A (es) 2011-05-24
AU2009347206B2 (en) 2015-08-20
US20160083452A1 (en) 2016-03-24
US8895709B2 (en) 2014-11-25
WO2010141039A1 (en) 2010-12-09
BRPI0920027A2 (pt) 2015-10-06
US20150210735A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
JP5808249B2 (ja) プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
JP6023140B2 (ja) 抗体精製中におけるウイルスの不活性化
AU2009307735B2 (en) Antibodies that bind to IL-12 and methods of purifying the same
JP2012506239A (ja) Ｉｌ−１８に結合する抗体およびそれを精製する方法
AU2015203650B2 (en) Viral inactivation during purification of antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121012

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150908

R150 Certificate of patent or registration of utility model

Ref document number: 5808249

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250